董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary Sender | 男 | Director | 57 | 13.04万美元 | 未持股 | 2020-02-06 |
| Ramy Farid | 男 | Chief Executive Officer and President, Director | 55 | 未披露 | 未持股 | 2020-02-06 |
| Richard A. Friesner | 男 | Director | 67 | 34.70万美元 | 未持股 | 2020-02-06 |
| Rosana Kapeller Libermann | 女 | Director | 56 | 13.02万美元 | 未持股 | 2020-02-06 |
| Nancy Thornberry | 女 | Director | 63 | 30.76万美元 | 未持股 | 2020-02-06 |
| Timothy M. Wright | 男 | Director | 64 | 未披露 | 未持股 | 2020-02-06 |
| Ramy Farid | 男 | Chief Executive Officer and President, Director | 55 | 63.31万美元 | 未持股 | 2020-02-06 |
| Michael Lynton | 男 | Chairman of the Board of Director | 60 | 未披露 | 未持股 | 2020-02-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ramy Farid | 男 | Chief Executive Officer and President, Director | 55 | 未披露 | 未持股 | 2020-02-06 |
| Robert Abel | -- | Executive Vice President, Science | 37 | 未披露 | 未持股 | 2020-02-06 |
| Karen Akinsanya | 女 | Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D | 52 | 未披露 | 未持股 | 2020-02-06 |
| Shane Brauner | 男 | Senior Vice President and Chief Information Officer | 42 | 未披露 | 未持股 | 2020-02-06 |
| Jennifer Daniel | 女 | Senior Vice President and Chief Human Resources Officer | 50 | 未披露 | 未持股 | 2020-02-06 |
| Cony D' Cruz | 男 | Executive Vice President and Chief Business Officer | 57 | 58.76万美元 | 未持股 | 2020-02-06 |
| Joel Lebowitz | 男 | Executive Vice President and Chief Financial Officer | 56 | 未披露 | 未持股 | 2020-02-06 |
| Kenneth Lorton | 男 | Senior Vice President and Chief Technology Officer | 36 | 未披露 | 未持股 | 2020-02-06 |
| Yvonne Tran | 女 | Executive Vice President and Chief Legal Officer | 49 | 54.76万美元 | 未持股 | 2020-02-06 |
| Jorg Weiser | -- | Executive Vice President and Managing Director | 52 | 未披露 | 未持股 | 2020-02-06 |
| Ramy Farid | 男 | Chief Executive Officer and President, Director | 55 | 63.31万美元 | 未持股 | 2020-02-06 |
董事简历
中英对照 | 中文 | 英文- Gary Sender
-
Gary Sender于2020年10月被任命为董事会成员，目前担任董事会审计委员会主席和薪酬委员会成员。Sender先生是一位高级执行官和董事会成员，在大型，跨国制药和早期生物技术公司拥有超过25年的财务领导经验。他曾担任Nabriva Therapeutics plc（Nasdaq:NBRV）的首席财务官，该公司是一家商业阶段的上市生物制药公司，自2016年5月起从事创新抗感染药物的商业化和开发，以治疗严重感染。在加入Nabriva之前，Sender先生于2015年11月至2016年4月担任Synergy PharmaceuticalsInc.执行Vice President兼首席财务官。此前，从2009年8月到2015年6月，森德还担任过Shire plc的财务高级副总裁，为其专业制药业务以及随后的全球商业业务提供支持。在加入Shire之前，Sender先生从2004年8月到2009年7月担任再生医学公司Tengion，Inc.的首席财务官。Sender先生还在默克公司（Merck&Co.）担任了15年多的领导职务。Inc.，一家制药公司。Sender先生目前在Harmony Biosciences（NASDAQ:HRMY）的董事会任职，并担任其审计委员会主席，并且是其薪酬委员会的成员，也在Schr&246；Dinger，Inc（NASDAQ:SDGR）的董事会任职，并担任其审计和薪酬委员会主席。他持有Boston University的财务和信息系统学士学位，以及Carnegie Mellon University的工商管理硕士学位。
Gary Sender was appointed as a member of iBio, Inc.'s Board of Directors in October 2020 and has served as the Lead Independent Director of the Board of Directors since December 2021. Mr. Sender currently serves as the Chair of the Audit Committee of the Board of Directors and as a member of iBio, Inc.'s Compensation Committee. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi-national pharmaceutical and early-stage biotechnology companies. In March 2021 Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial-stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015 Mr. Sender served as Senior Vice President of Finance of Shire Plc's "Shire", a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender currently serves on the Board of Directors of Schrodinger, Inc. and is the Chairman of their Audit and Compensation Committees. Mr. Sender also serves on the board of directors of Harmony Biosciences and is the Chairman of their Audit Committee and is a member on their Compensation Committee. Mr. Sender serves on the boards of Elucida Oncology and Gennao Bio - both privately held biotechnology firms. He is the Chairman of the Audit Committee of Elucida and Chairs both the Audit and Compensation Committees of Gennao. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie-Mellon University. - Gary Sender于2020年10月被任命为董事会成员，目前担任董事会审计委员会主席和薪酬委员会成员。Sender先生是一位高级执行官和董事会成员，在大型，跨国制药和早期生物技术公司拥有超过25年的财务领导经验。他曾担任Nabriva Therapeutics plc（Nasdaq:NBRV）的首席财务官，该公司是一家商业阶段的上市生物制药公司，自2016年5月起从事创新抗感染药物的商业化和开发，以治疗严重感染。在加入Nabriva之前，Sender先生于2015年11月至2016年4月担任Synergy PharmaceuticalsInc.执行Vice President兼首席财务官。此前，从2009年8月到2015年6月，森德还担任过Shire plc的财务高级副总裁，为其专业制药业务以及随后的全球商业业务提供支持。在加入Shire之前，Sender先生从2004年8月到2009年7月担任再生医学公司Tengion，Inc.的首席财务官。Sender先生还在默克公司（Merck&Co.）担任了15年多的领导职务。Inc.，一家制药公司。Sender先生目前在Harmony Biosciences（NASDAQ:HRMY）的董事会任职，并担任其审计委员会主席，并且是其薪酬委员会的成员，也在Schr&246；Dinger，Inc（NASDAQ:SDGR）的董事会任职，并担任其审计和薪酬委员会主席。他持有Boston University的财务和信息系统学士学位，以及Carnegie Mellon University的工商管理硕士学位。
- Gary Sender was appointed as a member of iBio, Inc.'s Board of Directors in October 2020 and has served as the Lead Independent Director of the Board of Directors since December 2021. Mr. Sender currently serves as the Chair of the Audit Committee of the Board of Directors and as a member of iBio, Inc.'s Compensation Committee. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi-national pharmaceutical and early-stage biotechnology companies. In March 2021 Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial-stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015 Mr. Sender served as Senior Vice President of Finance of Shire Plc's "Shire", a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender currently serves on the Board of Directors of Schrodinger, Inc. and is the Chairman of their Audit and Compensation Committees. Mr. Sender also serves on the board of directors of Harmony Biosciences and is the Chairman of their Audit Committee and is a member on their Compensation Committee. Mr. Sender serves on the boards of Elucida Oncology and Gennao Bio - both privately held biotechnology firms. He is the Chairman of the Audit Committee of Elucida and Chairs both the Audit and Compensation Committees of Gennao. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie-Mellon University.
- Ramy Farid
-
Ramy Farid自2008年1月起担任总裁，自2017年1月起担任首席执行官，自2012年12月起担任董事会成员。Farid博士在我们公司任职超过17年，从2005年1月到2007年12月担任高级副总裁，从2003年1月到2004年12月担任Vice President、科学发展和产品管理，从2002年1月到2002年12月担任产品经理。Farid博士担任由我们共同创立的多家生物技术公司的董事会成员，并曾担任生物技术公司MorphicHolding，Inc.的董事会成员。加入我们公司之前，Farid博士是罗格斯大学（Rutgers University）化学系的助理教授。Farid博士在罗切斯特大学（University of Rochester）获得化学学士学位，在加州理工学院（California Institute of Technology）获得博士学位，他是宾夕法尼亚大学（University of Pennsylvania）生物化学与生物物理系的国家卫生研究院博士后。
Ramy Farid has served as our president since January 2008 our chief executive officer since January 2017 and as a member of our board of directors since December 2012. Dr. Farid has been with our company for over 17 years and has served as senior vice president from January 2005 to December 2007 vice president, scientific development and product management from January 2003 to December 2004 and product manager from January 2002 to December 2002. Dr. Farid serves on the board of directors of multiple biotechnology companies co-founded by us, and previously served on the board of directors of Morphic Holding, Inc., a biotechnology company. Prior to joining our company, Dr. Farid was an assistant professor in the Chemistry Department at Rutgers University. Dr. Farid received a B.S. in Chemistry from the University of Rochester and a Ph.D. from the California Institute of Technology, and he was a National Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. - Ramy Farid自2008年1月起担任总裁，自2017年1月起担任首席执行官，自2012年12月起担任董事会成员。Farid博士在我们公司任职超过17年，从2005年1月到2007年12月担任高级副总裁，从2003年1月到2004年12月担任Vice President、科学发展和产品管理，从2002年1月到2002年12月担任产品经理。Farid博士担任由我们共同创立的多家生物技术公司的董事会成员，并曾担任生物技术公司MorphicHolding，Inc.的董事会成员。加入我们公司之前，Farid博士是罗格斯大学（Rutgers University）化学系的助理教授。Farid博士在罗切斯特大学（University of Rochester）获得化学学士学位，在加州理工学院（California Institute of Technology）获得博士学位，他是宾夕法尼亚大学（University of Pennsylvania）生物化学与生物物理系的国家卫生研究院博士后。
- Ramy Farid has served as our president since January 2008 our chief executive officer since January 2017 and as a member of our board of directors since December 2012. Dr. Farid has been with our company for over 17 years and has served as senior vice president from January 2005 to December 2007 vice president, scientific development and product management from January 2003 to December 2004 and product manager from January 2002 to December 2002. Dr. Farid serves on the board of directors of multiple biotechnology companies co-founded by us, and previously served on the board of directors of Morphic Holding, Inc., a biotechnology company. Prior to joining our company, Dr. Farid was an assistant professor in the Chemistry Department at Rutgers University. Dr. Farid received a B.S. in Chemistry from the University of Rochester and a Ph.D. from the California Institute of Technology, and he was a National Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania.
- Richard A. Friesner
-
RichardA.Friesner自1990年8月以来一直担任我们的董事会成员，当时他共同创立了我们。Friesner博士目前是哥伦比亚大学（Columbia University）的William P.Schweitzer化学教授，是哥伦比亚大学（Columbia University）化学系内的研究实验室Friesner Research Group的首席研究员，他自1990年9月起担任哥伦比亚大学（Columbia University）的化学教授。Friesner博士是美国科学院院士和美国国家科学院院士。Friesner博士在芝加哥大学（University of Chicago）获得化学学士学位，在加州大学伯克利分校（University of California，Berkeley）获得化学博士学位。
Richard A. Friesner has served as a member of our board of directors since August 1990 when he co-founded us. Dr. Friesner is currently the William P. Schweitzer professor of chemistry at Columbia University, the principal investigator of the Friesner Research Group, a research laboratory within the Department of Chemistry at Columbia University, and he has served as a professor of chemistry at Columbia Universiy since September 1990. Dr. Friesner is a Fellow of the American Academy of Sciences and a member of the National Academy of Sciences. Dr. Friesner received a B.S. in Chemistry from the University of Chicago and a Ph.D. in Chemistry from the University of California, Berkeley. - RichardA.Friesner自1990年8月以来一直担任我们的董事会成员，当时他共同创立了我们。Friesner博士目前是哥伦比亚大学（Columbia University）的William P.Schweitzer化学教授，是哥伦比亚大学（Columbia University）化学系内的研究实验室Friesner Research Group的首席研究员，他自1990年9月起担任哥伦比亚大学（Columbia University）的化学教授。Friesner博士是美国科学院院士和美国国家科学院院士。Friesner博士在芝加哥大学（University of Chicago）获得化学学士学位，在加州大学伯克利分校（University of California，Berkeley）获得化学博士学位。
- Richard A. Friesner has served as a member of our board of directors since August 1990 when he co-founded us. Dr. Friesner is currently the William P. Schweitzer professor of chemistry at Columbia University, the principal investigator of the Friesner Research Group, a research laboratory within the Department of Chemistry at Columbia University, and he has served as a professor of chemistry at Columbia Universiy since September 1990. Dr. Friesner is a Fellow of the American Academy of Sciences and a member of the National Academy of Sciences. Dr. Friesner received a B.S. in Chemistry from the University of Chicago and a Ph.D. in Chemistry from the University of California, Berkeley.
- Rosana Kapeller Libermann
-
Rosana Kapeller Libermann自2019年1月以来一直担任我们的董事会成员。Kapeller-Libermann博士自2019年4月起担任治疗公司Rome Therapeutics，Inc.的总裁兼首席执行官。自2018年11月起，她还担任AlphabetInc.旗下风险投资公司GV的常驻企业家。在此之前，Kapeller-Libermann博士于2010年2月至2018年3月担任生物技术公司Nimbus Therapeutics或Nimbus的创始首席科学官。在加入Nimbus之前，她曾于2005年8月至2009年9月担任生物制药公司AileronTherapeutics，Inc.的研究Vice President。Kapeller-Libermann博士在里约热内卢州立大学（Universidade do Estado do Rio de Janeiro）获得医学博士学位，并在塔夫茨大学（Tufts University）获得分子和细胞生理学博士学位。
Rosana Kapeller Libermann has served as a member of our board of directors since January 2019. Dr. Kapeller-Libermann has served as president and chief executive officer of Rome Therapeutics, Inc., a therapeutics company, since April 2019. She has also served as an entrepreneur in residence at GV, a venture capital investment arm of Alphabet Inc. since November 2018. Prior to that, Dr. Kapeller-Libermann served as founding chief scientific officer of Nimbus Therapeutics, or Nimbus, a biotechnology company, from February 2010 to March 2018. Prior to joining Nimbus, she served as vice president of research at Aileron Therapeutics, Inc., a biopharmaceutical company, from August 2005 to September 2009. Dr. Kapeller-Libermann received an M.D. from Universidade do Estado do Rio de Janeiro and a Ph.D. in Molecular and Cellular Physiology from Tufts University. - Rosana Kapeller Libermann自2019年1月以来一直担任我们的董事会成员。Kapeller-Libermann博士自2019年4月起担任治疗公司Rome Therapeutics，Inc.的总裁兼首席执行官。自2018年11月起，她还担任AlphabetInc.旗下风险投资公司GV的常驻企业家。在此之前，Kapeller-Libermann博士于2010年2月至2018年3月担任生物技术公司Nimbus Therapeutics或Nimbus的创始首席科学官。在加入Nimbus之前，她曾于2005年8月至2009年9月担任生物制药公司AileronTherapeutics，Inc.的研究Vice President。Kapeller-Libermann博士在里约热内卢州立大学（Universidade do Estado do Rio de Janeiro）获得医学博士学位，并在塔夫茨大学（Tufts University）获得分子和细胞生理学博士学位。
- Rosana Kapeller Libermann has served as a member of our board of directors since January 2019. Dr. Kapeller-Libermann has served as president and chief executive officer of Rome Therapeutics, Inc., a therapeutics company, since April 2019. She has also served as an entrepreneur in residence at GV, a venture capital investment arm of Alphabet Inc. since November 2018. Prior to that, Dr. Kapeller-Libermann served as founding chief scientific officer of Nimbus Therapeutics, or Nimbus, a biotechnology company, from February 2010 to March 2018. Prior to joining Nimbus, she served as vice president of research at Aileron Therapeutics, Inc., a biopharmaceutical company, from August 2005 to September 2009. Dr. Kapeller-Libermann received an M.D. from Universidade do Estado do Rio de Janeiro and a Ph.D. in Molecular and Cellular Physiology from Tufts University.
- Nancy Thornberry
-
Nancy Thornberry从2015年至2021年担任私人生物技术公司Kallyope, Inc.（以下简称Kallyope）的首席执行官，并继续担任该公司的董事会成员和研发主席。在加入Kallyope之前，Thornberry于2013年至2015年期间作为自由职业顾问为生物技术和制药行业的公司提供咨询服务。在此之前，她在制药公司默克（Merck & Co., Inc.）任职超过30年，担任过多个职位，最近一次是高级副总裁兼糖尿病和内分泌领域负责人。她目前担任公开生物技术公司Denali Therapeutics, Inc.和公开软件公司Schrdinger, Inc.的董事会成员。Thornberry于2013年至2020年期间担任私人生物技术研究公司Intarcia Therapeutics, Inc.的董事会成员，并于2014年至2019年担任生物技术公司Abide Therapeutics, Inc.的董事会成员，后者在2019年被H. Lundbeck A/S收购。Thornberry拥有Muhlenberg学院的化学和生物学学士学位。
Nancy Thornberry,Founder and Chief Executive Officer of Kallyope, Inc. ("Kallyope"), a private biotechnology company, from November 2015 to October 2021, and served as Chair of Research and Development through December 2023;Self-employed as a consultant to companies in the biotechnology and pharmaceutical industries from August 2013 to October 2015;Served in roles on increasing responsibility at Merck & Co., Inc., a pharmaceutical company, for more than 30 years, most recently as Senior Vice President and Franchise Head, Diabetes and Endocrinology;Holds a B.S. in Chemistry and Biology from Muhlenberg College. - Nancy Thornberry从2015年至2021年担任私人生物技术公司Kallyope, Inc.（以下简称Kallyope）的首席执行官，并继续担任该公司的董事会成员和研发主席。在加入Kallyope之前，Thornberry于2013年至2015年期间作为自由职业顾问为生物技术和制药行业的公司提供咨询服务。在此之前，她在制药公司默克（Merck & Co., Inc.）任职超过30年，担任过多个职位，最近一次是高级副总裁兼糖尿病和内分泌领域负责人。她目前担任公开生物技术公司Denali Therapeutics, Inc.和公开软件公司Schrdinger, Inc.的董事会成员。Thornberry于2013年至2020年期间担任私人生物技术研究公司Intarcia Therapeutics, Inc.的董事会成员，并于2014年至2019年担任生物技术公司Abide Therapeutics, Inc.的董事会成员，后者在2019年被H. Lundbeck A/S收购。Thornberry拥有Muhlenberg学院的化学和生物学学士学位。
- Nancy Thornberry,Founder and Chief Executive Officer of Kallyope, Inc. ("Kallyope"), a private biotechnology company, from November 2015 to October 2021, and served as Chair of Research and Development through December 2023;Self-employed as a consultant to companies in the biotechnology and pharmaceutical industries from August 2013 to October 2015;Served in roles on increasing responsibility at Merck & Co., Inc., a pharmaceutical company, for more than 30 years, most recently as Senior Vice President and Franchise Head, Diabetes and Endocrinology;Holds a B.S. in Chemistry and Biology from Muhlenberg College.
- Timothy M. Wright
-
TimothyM.Wright自2019年以来一直担任监督董事。自2019年以来，Wright博士是Time BioVentures的普通合伙人，自2015年以来还担任Schrodinger的董事。赖特博士于2016年至2019年担任Regulus Therapeutics的首席研究与开发官。任职Regulus公司之前，他曾担任加州生物医学研究所（California Institute for Biomedical Research）的执行Vice President（2015年至2016年）。Wright从2004年到2014年在Novartis and Novartis Institute for Biomedical Research担任越来越重要的职位，最终担任制药开发全球主管。他也曾担任Pfizer公司的越来越重要的职务，最终担任高级董事，负责临床科学/临床探索性头部炎症（从2001年到2004年）。Wright博士从1991年到2001年担任匹兹堡大学（University of Pittsburgh）助理教授、终身教授、风湿病与临床免疫学首席以及UPMC关节炎研究所所长。Wright从1983年到1991年担任Johns Hopkins University School of Medicine博士后、讲师和助理教授。Wright博士在特拉华大学（University of Delaware）获得生物学学士学位，并在约翰霍普金斯大学医学院（Johns Hopkins University School of Medicine）获得医学博士学位，在那里他还完成了博士后培训。
Timothy M. Wright has served as a supervisory director since 2019. Since 2019 Dr. Wright is a General Partner at TIME BioVentures, and has also served as director of Schrodinger since 2015. Dr. Wright served as the Chief Research and Development Officer for Regulus Therapeutics from 2016 until 2019. Prior to Regulus, he served as Executive Vice President of Translational Science at California Institute for Biomedical Research Between from 2015 until 2016. Between 2004 to 2014 Dr. Wright held positions of increasing importance at Novartis and Novartis Institute for Biomedical Research, culminating as Global Head of Pharma Development. He also served in roles of increasing importance at Pfizer, ultimately as Senior Director, Clinical Sciences / Clinical Exploratory Head - Inflammation between 2001 until 2004. Dr. Wright was Assistant Professor, Associate Professor with tenure, Chief of Rheumatology and Clinical Immunology, and Director of the UPMC Arthritis Institute at the University of Pittsburgh from 1991 until 2001. From 1983 to 1991 Dr. Wright was a postdoctoral fellow, Instructor and Assistant Professor at the Johns Hopkins University School of Medicine. Dr. Wright received a B.A. in Biology from the University of Delaware and an M.D. from the Johns Hopkins University School of Medicine, where he also completed post-doctoral training. - TimothyM.Wright自2019年以来一直担任监督董事。自2019年以来，Wright博士是Time BioVentures的普通合伙人，自2015年以来还担任Schrodinger的董事。赖特博士于2016年至2019年担任Regulus Therapeutics的首席研究与开发官。任职Regulus公司之前，他曾担任加州生物医学研究所（California Institute for Biomedical Research）的执行Vice President（2015年至2016年）。Wright从2004年到2014年在Novartis and Novartis Institute for Biomedical Research担任越来越重要的职位，最终担任制药开发全球主管。他也曾担任Pfizer公司的越来越重要的职务，最终担任高级董事，负责临床科学/临床探索性头部炎症（从2001年到2004年）。Wright博士从1991年到2001年担任匹兹堡大学（University of Pittsburgh）助理教授、终身教授、风湿病与临床免疫学首席以及UPMC关节炎研究所所长。Wright从1983年到1991年担任Johns Hopkins University School of Medicine博士后、讲师和助理教授。Wright博士在特拉华大学（University of Delaware）获得生物学学士学位，并在约翰霍普金斯大学医学院（Johns Hopkins University School of Medicine）获得医学博士学位，在那里他还完成了博士后培训。
- Timothy M. Wright has served as a supervisory director since 2019. Since 2019 Dr. Wright is a General Partner at TIME BioVentures, and has also served as director of Schrodinger since 2015. Dr. Wright served as the Chief Research and Development Officer for Regulus Therapeutics from 2016 until 2019. Prior to Regulus, he served as Executive Vice President of Translational Science at California Institute for Biomedical Research Between from 2015 until 2016. Between 2004 to 2014 Dr. Wright held positions of increasing importance at Novartis and Novartis Institute for Biomedical Research, culminating as Global Head of Pharma Development. He also served in roles of increasing importance at Pfizer, ultimately as Senior Director, Clinical Sciences / Clinical Exploratory Head - Inflammation between 2001 until 2004. Dr. Wright was Assistant Professor, Associate Professor with tenure, Chief of Rheumatology and Clinical Immunology, and Director of the UPMC Arthritis Institute at the University of Pittsburgh from 1991 until 2001. From 1983 to 1991 Dr. Wright was a postdoctoral fellow, Instructor and Assistant Professor at the Johns Hopkins University School of Medicine. Dr. Wright received a B.A. in Biology from the University of Delaware and an M.D. from the Johns Hopkins University School of Medicine, where he also completed post-doctoral training.
- Ramy Farid
-
Ramy Farid，自2019年4月起担任Structure Therapeutics公司董事会成员。Farid博士自2017年1月起在薛定谔公司（Nasdaq：SDGR）担任总裁兼首席执行官，自1987年起担任多个职务，包括2008年1月至2016年12月担任总裁、2005年1月至2007年12月担任高级副总裁、2003年1月至2004年12月担任科学发展和产品管理副总裁。在加入薛定谔之前，Farid博士于1994年7月至2001年12月担任罗格斯大学化学系助理教授。Farid博士目前担任Schr dinger和Ajax Therapeutics，Inc.的董事会成员。Ajax Therapeutics，Inc.是一家私营生物技术公司，应用计算化学和基于结构的技术开发用于血液系统恶性肿瘤的小分子。Farid博士以前是宾夕法尼亚大学生物化学和生物物理系的国家卫生研究所博士后研究员。Farid博士在罗切斯特大学获得化学学士学位，在加州理工学院获得化学博士学位。
Ramy Farid,has served as a member of Structure Therapeutics Inc. board of directors since April 2019. Since January 2017, Dr. Farid has served as the President and Chief Executive Officer at Schrodinger, Inc. (Nasdaq: SDGR), where he has served in various roles since 1987, including President from January 2008 to December 2016, Senior Vice President from January 2005 to December 2007, and Vice President, Scientific Development and Product Management from January 2003 to December 2004. Prior to joining Schrodinger, Dr. Farid was an Assistant Professor in the Chemistry Department at Rutgers University from July 1994 to December 2001. Dr. Farid currently serves as a member of the board of directors of Schrdinger and Ajax Therapeutics, Inc. a private biotechnology company applying computational chemistry and structure-based technologies to develop small molecules for hematologic malignancies. Dr. Farid was previously a National Institute of Health Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. Dr. Farid received his B.S. in Chemistry from the University of Rochester and his Ph.D. in Chemistry from the California Institute of Technology. - Ramy Farid，自2019年4月起担任Structure Therapeutics公司董事会成员。Farid博士自2017年1月起在薛定谔公司（Nasdaq：SDGR）担任总裁兼首席执行官，自1987年起担任多个职务，包括2008年1月至2016年12月担任总裁、2005年1月至2007年12月担任高级副总裁、2003年1月至2004年12月担任科学发展和产品管理副总裁。在加入薛定谔之前，Farid博士于1994年7月至2001年12月担任罗格斯大学化学系助理教授。Farid博士目前担任Schr dinger和Ajax Therapeutics，Inc.的董事会成员。Ajax Therapeutics，Inc.是一家私营生物技术公司，应用计算化学和基于结构的技术开发用于血液系统恶性肿瘤的小分子。Farid博士以前是宾夕法尼亚大学生物化学和生物物理系的国家卫生研究所博士后研究员。Farid博士在罗切斯特大学获得化学学士学位，在加州理工学院获得化学博士学位。
- Ramy Farid,has served as a member of Structure Therapeutics Inc. board of directors since April 2019. Since January 2017, Dr. Farid has served as the President and Chief Executive Officer at Schrodinger, Inc. (Nasdaq: SDGR), where he has served in various roles since 1987, including President from January 2008 to December 2016, Senior Vice President from January 2005 to December 2007, and Vice President, Scientific Development and Product Management from January 2003 to December 2004. Prior to joining Schrodinger, Dr. Farid was an Assistant Professor in the Chemistry Department at Rutgers University from July 1994 to December 2001. Dr. Farid currently serves as a member of the board of directors of Schrdinger and Ajax Therapeutics, Inc. a private biotechnology company applying computational chemistry and structure-based technologies to develop small molecules for hematologic malignancies. Dr. Farid was previously a National Institute of Health Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. Dr. Farid received his B.S. in Chemistry from the University of Rochester and his Ph.D. in Chemistry from the California Institute of Technology.
- Michael Lynton
-
Michael Lynton担任Sony Entertainmen首席执行官，负责Sony全球娱乐业务，包括索尼音乐娱乐、Sony / ATV音乐出版和索尼影视娱乐。他担任是索尼影视娱乐公司主席兼首席执行长和管理工作室的全球业务，其中包括电影、电视和数字内容生产和分配，家庭娱乐的收购和销售，经营工作室设施和新娱乐产品的开发和技术服务。加入索尼之前，他在时代华纳工作，担任AOL Europe首席执行官，AOL International总裁和Time Warner International总裁。从1996年到2000年，他担任Pearson plc''s Penguin Group主席兼首席执行官。他于1987年加入华特迪士尼公司，负责迪斯尼出版工作。从1992年到1996年，他担任迪斯尼好莱坞照片总裁。他目前是Snapchat董事会成员。他担任外交关系委员会成员和哈佛董事会负责人，洛杉矶县艺术博物馆董事会成员，在南加州大学电影艺术学院和兰德公司工作。他拥有哈佛大学历史与文学学位和MBA。
Michael Lynton,has served on Snap Inc. board of directors since April 2013 and has been Chairperson of Snap Inc. board of directors since September 2016. Mr. Lynton served as Chief Executive Officer or Co-Chief Executive Officer of Sony Entertainment Inc., an international entertainment company, from April 2012 until August 2017, as Chairman and Chief Executive Officer of Sony Pictures Entertainment Inc. from January 2004 until May 2017, and as CEO of Sony Corporation of America from March 2012 to August 2017. Mr. Lynton has served as a member of the board of directors of Ares Management Corporation since 2014, Warner Music Group Corp. since 2019, and Schrodinger, Inc. since 2018. Mr. Lynton also served as a member of the board of directors of Pandora Media, Inc., Pearson plc, and The Boston Beer Company. Mr. Lynton holds a B.A. in History and Literature from Harvard College and an M.B.A. from Harvard Business School. - Michael Lynton担任Sony Entertainmen首席执行官，负责Sony全球娱乐业务，包括索尼音乐娱乐、Sony / ATV音乐出版和索尼影视娱乐。他担任是索尼影视娱乐公司主席兼首席执行长和管理工作室的全球业务，其中包括电影、电视和数字内容生产和分配，家庭娱乐的收购和销售，经营工作室设施和新娱乐产品的开发和技术服务。加入索尼之前，他在时代华纳工作，担任AOL Europe首席执行官，AOL International总裁和Time Warner International总裁。从1996年到2000年，他担任Pearson plc''s Penguin Group主席兼首席执行官。他于1987年加入华特迪士尼公司，负责迪斯尼出版工作。从1992年到1996年，他担任迪斯尼好莱坞照片总裁。他目前是Snapchat董事会成员。他担任外交关系委员会成员和哈佛董事会负责人，洛杉矶县艺术博物馆董事会成员，在南加州大学电影艺术学院和兰德公司工作。他拥有哈佛大学历史与文学学位和MBA。
- Michael Lynton,has served on Snap Inc. board of directors since April 2013 and has been Chairperson of Snap Inc. board of directors since September 2016. Mr. Lynton served as Chief Executive Officer or Co-Chief Executive Officer of Sony Entertainment Inc., an international entertainment company, from April 2012 until August 2017, as Chairman and Chief Executive Officer of Sony Pictures Entertainment Inc. from January 2004 until May 2017, and as CEO of Sony Corporation of America from March 2012 to August 2017. Mr. Lynton has served as a member of the board of directors of Ares Management Corporation since 2014, Warner Music Group Corp. since 2019, and Schrodinger, Inc. since 2018. Mr. Lynton also served as a member of the board of directors of Pandora Media, Inc., Pearson plc, and The Boston Beer Company. Mr. Lynton holds a B.A. in History and Literature from Harvard College and an M.B.A. from Harvard Business School.
高管简历
中英对照 | 中文 | 英文- Ramy Farid
Ramy Farid自2008年1月起担任总裁，自2017年1月起担任首席执行官，自2012年12月起担任董事会成员。Farid博士在我们公司任职超过17年，从2005年1月到2007年12月担任高级副总裁，从2003年1月到2004年12月担任Vice President、科学发展和产品管理，从2002年1月到2002年12月担任产品经理。Farid博士担任由我们共同创立的多家生物技术公司的董事会成员，并曾担任生物技术公司MorphicHolding，Inc.的董事会成员。加入我们公司之前，Farid博士是罗格斯大学（Rutgers University）化学系的助理教授。Farid博士在罗切斯特大学（University of Rochester）获得化学学士学位，在加州理工学院（California Institute of Technology）获得博士学位，他是宾夕法尼亚大学（University of Pennsylvania）生物化学与生物物理系的国家卫生研究院博士后。
Ramy Farid has served as our president since January 2008 our chief executive officer since January 2017 and as a member of our board of directors since December 2012. Dr. Farid has been with our company for over 17 years and has served as senior vice president from January 2005 to December 2007 vice president, scientific development and product management from January 2003 to December 2004 and product manager from January 2002 to December 2002. Dr. Farid serves on the board of directors of multiple biotechnology companies co-founded by us, and previously served on the board of directors of Morphic Holding, Inc., a biotechnology company. Prior to joining our company, Dr. Farid was an assistant professor in the Chemistry Department at Rutgers University. Dr. Farid received a B.S. in Chemistry from the University of Rochester and a Ph.D. from the California Institute of Technology, and he was a National Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania.- Ramy Farid自2008年1月起担任总裁，自2017年1月起担任首席执行官，自2012年12月起担任董事会成员。Farid博士在我们公司任职超过17年，从2005年1月到2007年12月担任高级副总裁，从2003年1月到2004年12月担任Vice President、科学发展和产品管理，从2002年1月到2002年12月担任产品经理。Farid博士担任由我们共同创立的多家生物技术公司的董事会成员，并曾担任生物技术公司MorphicHolding，Inc.的董事会成员。加入我们公司之前，Farid博士是罗格斯大学（Rutgers University）化学系的助理教授。Farid博士在罗切斯特大学（University of Rochester）获得化学学士学位，在加州理工学院（California Institute of Technology）获得博士学位，他是宾夕法尼亚大学（University of Pennsylvania）生物化学与生物物理系的国家卫生研究院博士后。
- Ramy Farid has served as our president since January 2008 our chief executive officer since January 2017 and as a member of our board of directors since December 2012. Dr. Farid has been with our company for over 17 years and has served as senior vice president from January 2005 to December 2007 vice president, scientific development and product management from January 2003 to December 2004 and product manager from January 2002 to December 2002. Dr. Farid serves on the board of directors of multiple biotechnology companies co-founded by us, and previously served on the board of directors of Morphic Holding, Inc., a biotechnology company. Prior to joining our company, Dr. Farid was an assistant professor in the Chemistry Department at Rutgers University. Dr. Farid received a B.S. in Chemistry from the University of Rochester and a Ph.D. from the California Institute of Technology, and he was a National Institutes of Health postdoctoral fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania.
- Robert Abel
Robert Abel自2020年1月起担任我们的执行Vice President Science。Abel博士在我们公司任职超过10年，此前曾于2017年4月至2019年12月Vice President担任我们的高级副总裁，科学，2014年1月至2017年4月担任结构科学总监，2011年1月至2013年12月担任高级首席科学家兼产品经理，2010年1月至2010年12月担任高级首席科学家，2009年3月至2009年12月担任高级科学家。Abel博士在佛罗里达大学（University of Florida）获得化学学士学位，在哥伦比亚大学（Columbia University）获得化学物理学博士学位。在研究生院，Abel博士是国家科学基金会研究生研究员和国土安全部研究员，并于2005年5月至2005年8月在DHS Research Fellowship主持下在洛斯阿拉莫斯国家实验室工作。
Robert Abel has served as our executive vice president, science, since January 2020. Dr. Abel has been with our company for over 10 years and previously served as our senior vice president, science, from April 2017 to December 2019 vice president, scientific development from January 2014 to April 2017 director of structure-based science from January 2011 to December 2013 senior principal scientist and product manager from January 2010 to December 2010 and senior scientist from March 2009 to December 2009. Dr. Abel received a B.S. in Chemistry from the University of Florida and a Ph.D. in Chemical Physics from Columbia University. In graduate school, Dr. Abel was a National Science Foundation Graduate Research Fellow and a Department of Homeland Security Research Fellow, and worked from May 2005 to August 2005 at Los Alamos National Laboratory under the auspices of the DHS Research Fellowship.- Robert Abel自2020年1月起担任我们的执行Vice President Science。Abel博士在我们公司任职超过10年，此前曾于2017年4月至2019年12月Vice President担任我们的高级副总裁，科学，2014年1月至2017年4月担任结构科学总监，2011年1月至2013年12月担任高级首席科学家兼产品经理，2010年1月至2010年12月担任高级首席科学家，2009年3月至2009年12月担任高级科学家。Abel博士在佛罗里达大学（University of Florida）获得化学学士学位，在哥伦比亚大学（Columbia University）获得化学物理学博士学位。在研究生院，Abel博士是国家科学基金会研究生研究员和国土安全部研究员，并于2005年5月至2005年8月在DHS Research Fellowship主持下在洛斯阿拉莫斯国家实验室工作。
- Robert Abel has served as our executive vice president, science, since January 2020. Dr. Abel has been with our company for over 10 years and previously served as our senior vice president, science, from April 2017 to December 2019 vice president, scientific development from January 2014 to April 2017 director of structure-based science from January 2011 to December 2013 senior principal scientist and product manager from January 2010 to December 2010 and senior scientist from March 2009 to December 2009. Dr. Abel received a B.S. in Chemistry from the University of Florida and a Ph.D. in Chemical Physics from Columbia University. In graduate school, Dr. Abel was a National Science Foundation Graduate Research Fellow and a Department of Homeland Security Research Fellow, and worked from May 2005 to August 2005 at Los Alamos National Laboratory under the auspices of the DHS Research Fellowship.
- Karen Akinsanya
Karen Akinsanya自2020年1月起担任我们的执行Vice President，首席生物医学科学家，发现研发主管，此前曾于2018年4月至2019年12月担任我们的高级副总裁兼首席生物医学科学家。Akinsanya博士在默克制药公司（默克制药公司）工作了12年，2013年12月至2017年7月，她在默克研究实验室（Merck Research Labs）担任多个职位，包括助理Vice President、早期科学评估主管、业务开发与许可主管和执行董事，2010年1月至2013年12月担任心血管研究，2005年10月至2009年12月担任临床药理学副主任。任职Merck公司之前，Akinsanya博士曾担任Ferring Pharmaceuticals公司（位于英国和美国）的多种药物发现职务（1997年至2005年）。她于2007年创立Envision Science Group LLC（翻译科学咨询公司），在那里她目前担任总裁。Akinsanya博士于2017年7月至2018年4月期间代表Envision向制药行业的公司提供咨询服务。Akinsanya博士获得了理学学士学位。在伦敦大学玛丽皇后学院获得生物化学博士学位，在帝国学院获得内分泌生理学博士学位，并在伦敦大学学院路德维希癌症研究所完成博士后学习。
Karen Akinsanya has served as our executive vice president, chief biomedical scientist, head of discovery R&D since January 2020 and previously served as our senior vice president and chief biomedical scientist from April 2018 to December 2019. Dr. Akinsanya spent 12 years at Merck & Co., Inc., or Merck, a pharmaceutical company, where she held a variety of positions across Merck Research Labs, including associate vice president, early scientific assessment lead, business development & licensing from December 2013 to July 2017 collaboration lead and executive director, cardiovascular research from January 2010 to December 2013 and associate director, clinical pharmacology from October 2005 to December 2009. Prior to Merck, Dr. Akinsanya held a number of roles in drug discovery at Ferring Pharmaceuticals in the United Kingdom and the United States from 1997 to 2005. In 2007 Dr. Akinsanya founded Envision Science Group LLC, or Envision, a translational science consulting company, where she currently serves as president. Dr. Akinsanya provided consulting services on behalf of Envision to companies in the pharmaceutical industry between July 2017 and April 2018. Dr. Akinsanya received a B.Sc. in Biochemistry from Queen Mary College, University of London, a Ph.D. in Endocrine Physiology from the Imperial College and completed postdoctoral studies at the Ludwig Institute for Cancer Research, University College, London.- Karen Akinsanya自2020年1月起担任我们的执行Vice President，首席生物医学科学家，发现研发主管，此前曾于2018年4月至2019年12月担任我们的高级副总裁兼首席生物医学科学家。Akinsanya博士在默克制药公司（默克制药公司）工作了12年，2013年12月至2017年7月，她在默克研究实验室（Merck Research Labs）担任多个职位，包括助理Vice President、早期科学评估主管、业务开发与许可主管和执行董事，2010年1月至2013年12月担任心血管研究，2005年10月至2009年12月担任临床药理学副主任。任职Merck公司之前，Akinsanya博士曾担任Ferring Pharmaceuticals公司（位于英国和美国）的多种药物发现职务（1997年至2005年）。她于2007年创立Envision Science Group LLC（翻译科学咨询公司），在那里她目前担任总裁。Akinsanya博士于2017年7月至2018年4月期间代表Envision向制药行业的公司提供咨询服务。Akinsanya博士获得了理学学士学位。在伦敦大学玛丽皇后学院获得生物化学博士学位，在帝国学院获得内分泌生理学博士学位，并在伦敦大学学院路德维希癌症研究所完成博士后学习。
- Karen Akinsanya has served as our executive vice president, chief biomedical scientist, head of discovery R&D since January 2020 and previously served as our senior vice president and chief biomedical scientist from April 2018 to December 2019. Dr. Akinsanya spent 12 years at Merck & Co., Inc., or Merck, a pharmaceutical company, where she held a variety of positions across Merck Research Labs, including associate vice president, early scientific assessment lead, business development & licensing from December 2013 to July 2017 collaboration lead and executive director, cardiovascular research from January 2010 to December 2013 and associate director, clinical pharmacology from October 2005 to December 2009. Prior to Merck, Dr. Akinsanya held a number of roles in drug discovery at Ferring Pharmaceuticals in the United Kingdom and the United States from 1997 to 2005. In 2007 Dr. Akinsanya founded Envision Science Group LLC, or Envision, a translational science consulting company, where she currently serves as president. Dr. Akinsanya provided consulting services on behalf of Envision to companies in the pharmaceutical industry between July 2017 and April 2018. Dr. Akinsanya received a B.Sc. in Biochemistry from Queen Mary College, University of London, a Ph.D. in Endocrine Physiology from the Imperial College and completed postdoctoral studies at the Ludwig Institute for Cancer Research, University College, London.
- Shane Brauner
Shane Brauner自2019年1月起担任我们的首席信息官。布劳纳先生在我们公司任职超过10年，此前曾于2017年1月至2019年1月担任我们的高级副总裁，信息系统Vice President，信息技术和运营执行董事，2014年1月至2015年1月担任信息技术和运营高级总监，2012年1月至2014年1月担任信息技术总监，2010年1月至2012年1月担任信息技术总监，2009年2月至2010年1月担任信息技术经理。加入公司之前，Brauner从2007年6月到2008年10月担任Pfizer，Inc.（Pfizer）顾问，管理全球网格计算支持。Brauner先生在休斯敦大学（University of Houston）获得计算机科学学士学位。
Shane Brauner has served as our chief information officer since January 2019. Mr. Brauner has been with our company for over 10 years and previously served as our senior vice president, information systems from January 2017 to January 2019 vice president, information technology and operations from January 2015 to January 2017 executive director, information technology and operations from January 2014 to January 2015 senior director, information technology from January 2012 to January 2014 director, information technology from January 2010 to January 2012 and manager, information technology from February 2009 to January 2010. Prior to joining our company, Mr. Brauner served as a consultant, managing global grid computing support at Pfizer, Inc., or Pfizer, from June 2007 to October 2008. Mr. Brauner received a B.S. in Computer Science from the University of Houston.- Shane Brauner自2019年1月起担任我们的首席信息官。布劳纳先生在我们公司任职超过10年，此前曾于2017年1月至2019年1月担任我们的高级副总裁，信息系统Vice President，信息技术和运营执行董事，2014年1月至2015年1月担任信息技术和运营高级总监，2012年1月至2014年1月担任信息技术总监，2010年1月至2012年1月担任信息技术总监，2009年2月至2010年1月担任信息技术经理。加入公司之前，Brauner从2007年6月到2008年10月担任Pfizer，Inc.（Pfizer）顾问，管理全球网格计算支持。Brauner先生在休斯敦大学（University of Houston）获得计算机科学学士学位。
- Shane Brauner has served as our chief information officer since January 2019. Mr. Brauner has been with our company for over 10 years and previously served as our senior vice president, information systems from January 2017 to January 2019 vice president, information technology and operations from January 2015 to January 2017 executive director, information technology and operations from January 2014 to January 2015 senior director, information technology from January 2012 to January 2014 director, information technology from January 2010 to January 2012 and manager, information technology from February 2009 to January 2010. Prior to joining our company, Mr. Brauner served as a consultant, managing global grid computing support at Pfizer, Inc., or Pfizer, from June 2007 to October 2008. Mr. Brauner received a B.S. in Computer Science from the University of Houston.
- Jennifer Daniel
Jennifer Daniel自2017年2月起担任我们的高级副总裁兼首席人力资源官，并于2002年1月至2009年6月担任我们的人力资源Vice President。在2017年2月重新加入我们公司之前，Daniel女士于2011年12月至2017年2月担任广告技术公司Outbrain Inc.的高级副总裁，人力资源。在此之前，Daniel女士从1996年6月到2001年10月担任Juno Online Services（一家互联网服务提供商）的高级副总裁，战略增长。Daniel女士在美国大学（American University）获得国际关系学士学位，并在宾夕法尼亚大学（University of Pennsylvania）获得环境研究硕士学位。
Jennifer Daniel has served as our senior vice president and chief human resources officer since February 2017 and as our vice president of human resources from January 2002 to June 2009. Prior to rejoining our company in February 2017 Ms. Daniel served as senior vice president, human resources at Outbrain Inc., an advertising technology company, from December 2011 to February 2017. Prior to that, Ms. Daniel served as senior vice president, strategic growth, at Juno Online Services, an internet service provider company, from June 1996 to October 2001. Ms. Daniel received a B.A. in International Relations from American University and an M.L.A, Environmental Studies from the University of Pennsylvania.- Jennifer Daniel自2017年2月起担任我们的高级副总裁兼首席人力资源官，并于2002年1月至2009年6月担任我们的人力资源Vice President。在2017年2月重新加入我们公司之前，Daniel女士于2011年12月至2017年2月担任广告技术公司Outbrain Inc.的高级副总裁，人力资源。在此之前，Daniel女士从1996年6月到2001年10月担任Juno Online Services（一家互联网服务提供商）的高级副总裁，战略增长。Daniel女士在美国大学（American University）获得国际关系学士学位，并在宾夕法尼亚大学（University of Pennsylvania）获得环境研究硕士学位。
- Jennifer Daniel has served as our senior vice president and chief human resources officer since February 2017 and as our vice president of human resources from January 2002 to June 2009. Prior to rejoining our company in February 2017 Ms. Daniel served as senior vice president, human resources at Outbrain Inc., an advertising technology company, from December 2011 to February 2017. Prior to that, Ms. Daniel served as senior vice president, strategic growth, at Juno Online Services, an internet service provider company, from June 1996 to October 2001. Ms. Daniel received a B.A. in International Relations from American University and an M.L.A, Environmental Studies from the University of Pennsylvania.
- Cony D' Cruz
ConyD’Cruz自2016年1月起担任我们的执行Vice President兼首席商务官。此前，D’Cruz先生曾于2013年4月至2015年12月担任我们的业务发展高级副总裁。在加入我们公司之前，D’Cruz先生于2010年至2013年3月担任Proteros US，Inc.或Proteros（一家生物技术公司）的总裁。在加入Proteros之前，D’Cruz先生曾于2001年至2010年在生物技术公司Evotec SE或Evotec担任北美高级副总裁，。D’Cruz先生获得工商管理学士学位。拥有伦敦大学应用生物学学士学位和英国米尔顿·凯恩斯开放大学工商管理硕士学位。
Cony D' Cruz has served as our executive vice president and chief business officer since January 2016. Previously, Mr. D'Cruz served as our senior vice president of business development from April 2013 to December 2015. Prior to joining our company, Mr. D'Cruz served as president of Proteros US, Inc., or Proteros, a biotechnology company, from 2010 to March 2013. Prior to joining Proteros, Mr. D'Cruz served as senior vice president, North America, at Evotec SE, or Evotec, a biotechnology company, from 2001 to 2010. Mr. D'Cruz received a B.Sc. in Applied Biology from the University of London and an M.B.A from The Open University, Milton Keynes United Kingdom.- ConyD’Cruz自2016年1月起担任我们的执行Vice President兼首席商务官。此前，D’Cruz先生曾于2013年4月至2015年12月担任我们的业务发展高级副总裁。在加入我们公司之前，D’Cruz先生于2010年至2013年3月担任Proteros US，Inc.或Proteros（一家生物技术公司）的总裁。在加入Proteros之前，D’Cruz先生曾于2001年至2010年在生物技术公司Evotec SE或Evotec担任北美高级副总裁，。D’Cruz先生获得工商管理学士学位。拥有伦敦大学应用生物学学士学位和英国米尔顿·凯恩斯开放大学工商管理硕士学位。
- Cony D' Cruz has served as our executive vice president and chief business officer since January 2016. Previously, Mr. D'Cruz served as our senior vice president of business development from April 2013 to December 2015. Prior to joining our company, Mr. D'Cruz served as president of Proteros US, Inc., or Proteros, a biotechnology company, from 2010 to March 2013. Prior to joining Proteros, Mr. D'Cruz served as senior vice president, North America, at Evotec SE, or Evotec, a biotechnology company, from 2001 to 2010. Mr. D'Cruz received a B.Sc. in Applied Biology from the University of London and an M.B.A from The Open University, Milton Keynes United Kingdom.
- Joel Lebowitz
Joel Lebowitz自2018年11月以来一直担任我们的执行Vice President和首席财务官。他此前曾任职Merck公司（制药公司）26年，在那里他曾担任全球财务主管、项目管理（从2013年9月到2014年12月）、管道估值和投资组合分析执行董事（从2011年10月到2014年3月）、执行董事（从2013年9月到2014年12月）。2005年至2011年公司规划和管理报告。2015年1月至2018年10月，Lebowitz先生退休。Lebowitz先生在布朗大学（Brown University）获得应用数学与经济学学士学位，并在哥伦比亚商学院（Columbia Graduate School of Business）获得金融与国际商务工商管理硕士学位。
Joel Lebowitz has served as our executive vice president and chief financial officer since November 2018. Mr. Lebowitz previously spent 26 years at Merck, a pharmaceutical company, where he served as global finance lead, project management from September 2013 to December 2014 executive director, pipeline valuation and portfolio analysis from October 2011 to March 2014 and executive director, corporate planning and management reporting from 2005 to 2011. From January 2015 to October 2018 Mr. Lebowitz was retired. Mr. Lebowitz received a B.A. in Applied Mathematics and Economics from Brown University and an M.B.A. in Finance and International Business from Columbia Graduate School of Business.- Joel Lebowitz自2018年11月以来一直担任我们的执行Vice President和首席财务官。他此前曾任职Merck公司（制药公司）26年，在那里他曾担任全球财务主管、项目管理（从2013年9月到2014年12月）、管道估值和投资组合分析执行董事（从2011年10月到2014年3月）、执行董事（从2013年9月到2014年12月）。2005年至2011年公司规划和管理报告。2015年1月至2018年10月，Lebowitz先生退休。Lebowitz先生在布朗大学（Brown University）获得应用数学与经济学学士学位，并在哥伦比亚商学院（Columbia Graduate School of Business）获得金融与国际商务工商管理硕士学位。
- Joel Lebowitz has served as our executive vice president and chief financial officer since November 2018. Mr. Lebowitz previously spent 26 years at Merck, a pharmaceutical company, where he served as global finance lead, project management from September 2013 to December 2014 executive director, pipeline valuation and portfolio analysis from October 2011 to March 2014 and executive director, corporate planning and management reporting from 2005 to 2011. From January 2015 to October 2018 Mr. Lebowitz was retired. Mr. Lebowitz received a B.A. in Applied Mathematics and Economics from Brown University and an M.B.A. in Finance and International Business from Columbia Graduate School of Business.
- Kenneth Lorton
Kenneth Lorton自2017年4月起担任我们的高级副总裁兼首席技术官。Lorton先生在我们公司任职超过13年曾于2016年1月至2017年4月担任我们的工程Vice President，2015年1月至2016年1月担任软件工程总监，2012年12月至2015年1月担任软件工程副总监，2011年1月至2012年12月担任项目负责人以及2006年9月至2012年12月的Scientific Developer。在加入我们公司之前，Lorton先生从2005年12月到2006年9月担任印第安纳大学布鲁明顿分校（Indiana University Bloomington）的化学研究助理，从2004年8月到2006年7月担任计算机科学研究助理。Lorton先生在印第安纳大学布鲁明顿分校（Indiana University Bloomington）获得计算机科学学士学位和数学与化学学士学位。
Kenneth Lorton has served as our senior vice president and chief technology officer since April 2017. Mr. Lorton has been with our company for over 13 years and previously served as our vice president of engineering from January 2016 to April 2017 director of software engineering from January 2015 to January 2016 associate director of software engineering from December 2012 to January 2015 project leader from January 2011 to December 2012 and scientific developer from September 2006 to December 2012. Prior to joining our company, Mr. Lorton served as a chemistry research assistant from December 2005 to September 2006 and a computer science research assistant from August 2004 to July 2006 at Indiana University Bloomington. Mr. Lorton received a B.S. in Computer Science and a B.A. in Mathematics and Chemistry from Indiana University Bloomington.- Kenneth Lorton自2017年4月起担任我们的高级副总裁兼首席技术官。Lorton先生在我们公司任职超过13年曾于2016年1月至2017年4月担任我们的工程Vice President，2015年1月至2016年1月担任软件工程总监，2012年12月至2015年1月担任软件工程副总监，2011年1月至2012年12月担任项目负责人以及2006年9月至2012年12月的Scientific Developer。在加入我们公司之前，Lorton先生从2005年12月到2006年9月担任印第安纳大学布鲁明顿分校（Indiana University Bloomington）的化学研究助理，从2004年8月到2006年7月担任计算机科学研究助理。Lorton先生在印第安纳大学布鲁明顿分校（Indiana University Bloomington）获得计算机科学学士学位和数学与化学学士学位。
- Kenneth Lorton has served as our senior vice president and chief technology officer since April 2017. Mr. Lorton has been with our company for over 13 years and previously served as our vice president of engineering from January 2016 to April 2017 director of software engineering from January 2015 to January 2016 associate director of software engineering from December 2012 to January 2015 project leader from January 2011 to December 2012 and scientific developer from September 2006 to December 2012. Prior to joining our company, Mr. Lorton served as a chemistry research assistant from December 2005 to September 2006 and a computer science research assistant from August 2004 to July 2006 at Indiana University Bloomington. Mr. Lorton received a B.S. in Computer Science and a B.A. in Mathematics and Chemistry from Indiana University Bloomington.
- Yvonne Tran
Yvonne Tran自2017年4月起担任我们的执行Vice President兼首席法务官，此前曾于2010年4月至2017年4月担任我们的总法律顾问。在加入我们公司之前，Tran女士曾于2008年1月至2010年4月担任Oracle America，Inc.或Oracle（一家技术公司）的高级公司法律顾问。加入Oracle之前，Tran从2006年1月到2008年1月担任DoubleClick，Inc.（一家广告技术公司，后被Google LLC收购）外部法律顾问，从2000年4月到2006年1月担任副总法律顾问。Tran女士在耶鲁大学（Yale University）获得分子生物物理学和生物化学学士学位，并在弗吉尼亚大学法学院（University of Virginia School of Law）获得法学博士学位。
Yvonne Tran has served as our executive vice president and chief legal officer since April 2017 and previously served as our general counsel from April 2010 to April 2017. Prior to joining our company, Ms. Tran previously served as senior corporate counsel at Oracle America, Inc., or Oracle, a technology company, from January 2008 to April 2010. Prior to joining Oracle, Ms. Tran served as outside legal consultant from January 2006 to January 2008 and deputy general counsel from April 2000 to January 2006 at DoubleClick, Inc., an advertising technology company since acquired by Google LLC. Ms. Tran received a B.A. in Molecular Biophysics and Biochemistry from Yale University and a J.D. from the University of Virginia School of Law.- Yvonne Tran自2017年4月起担任我们的执行Vice President兼首席法务官，此前曾于2010年4月至2017年4月担任我们的总法律顾问。在加入我们公司之前，Tran女士曾于2008年1月至2010年4月担任Oracle America，Inc.或Oracle（一家技术公司）的高级公司法律顾问。加入Oracle之前，Tran从2006年1月到2008年1月担任DoubleClick，Inc.（一家广告技术公司，后被Google LLC收购）外部法律顾问，从2000年4月到2006年1月担任副总法律顾问。Tran女士在耶鲁大学（Yale University）获得分子生物物理学和生物化学学士学位，并在弗吉尼亚大学法学院（University of Virginia School of Law）获得法学博士学位。
- Yvonne Tran has served as our executive vice president and chief legal officer since April 2017 and previously served as our general counsel from April 2010 to April 2017. Prior to joining our company, Ms. Tran previously served as senior corporate counsel at Oracle America, Inc., or Oracle, a technology company, from January 2008 to April 2010. Prior to joining Oracle, Ms. Tran served as outside legal consultant from January 2006 to January 2008 and deputy general counsel from April 2000 to January 2006 at DoubleClick, Inc., an advertising technology company since acquired by Google LLC. Ms. Tran received a B.A. in Molecular Biophysics and Biochemistry from Yale University and a J.D. from the University of Virginia School of Law.
- Jorg Weiser
Jorg Weiser自2002年10月以来一直担任我们德国办事处和全资子公司Schrodinger GmbH的执行Vice President和董事总经理。Weiser之前从1999年6月到2002年9月担任Anterio Consult&Research GmbH（一家德国咨询和研究公司）联合创始人和董事总经理。Weiser博士在哥廷根大学（University of Gottingen）获得有机化学博士学位，曾是哥伦比亚大学（Columbia University）的博士后。
Jorg Weiser has served as the executive vice president and managing director of our German office and wholly owned subsidiary, Schrodinger GmbH, since October 2002. Dr. Weiser previously served as co-founder and managing director at Anterio Consult & Research GmbH, a German consulting and research company, from June 1999 to September 2002. Dr. Weiser received a doctorate in Organic Chemistry from the University of Gottingen and was a post-doctoral fellow at Columbia University.- Jorg Weiser自2002年10月以来一直担任我们德国办事处和全资子公司Schrodinger GmbH的执行Vice President和董事总经理。Weiser之前从1999年6月到2002年9月担任Anterio Consult&Research GmbH（一家德国咨询和研究公司）联合创始人和董事总经理。Weiser博士在哥廷根大学（University of Gottingen）获得有机化学博士学位，曾是哥伦比亚大学（Columbia University）的博士后。
- Jorg Weiser has served as the executive vice president and managing director of our German office and wholly owned subsidiary, Schrodinger GmbH, since October 2002. Dr. Weiser previously served as co-founder and managing director at Anterio Consult & Research GmbH, a German consulting and research company, from June 1999 to September 2002. Dr. Weiser received a doctorate in Organic Chemistry from the University of Gottingen and was a post-doctoral fellow at Columbia University.
- Ramy Farid
Ramy Farid，自2019年4月起担任Structure Therapeutics公司董事会成员。Farid博士自2017年1月起在薛定谔公司（Nasdaq：SDGR）担任总裁兼首席执行官，自1987年起担任多个职务，包括2008年1月至2016年12月担任总裁、2005年1月至2007年12月担任高级副总裁、2003年1月至2004年12月担任科学发展和产品管理副总裁。在加入薛定谔之前，Farid博士于1994年7月至2001年12月担任罗格斯大学化学系助理教授。Farid博士目前担任Schr dinger和Ajax Therapeutics，Inc.的董事会成员。Ajax Therapeutics，Inc.是一家私营生物技术公司，应用计算化学和基于结构的技术开发用于血液系统恶性肿瘤的小分子。Farid博士以前是宾夕法尼亚大学生物化学和生物物理系的国家卫生研究所博士后研究员。Farid博士在罗切斯特大学获得化学学士学位，在加州理工学院获得化学博士学位。
Ramy Farid,has served as a member of Structure Therapeutics Inc. board of directors since April 2019. Since January 2017, Dr. Farid has served as the President and Chief Executive Officer at Schrodinger, Inc. (Nasdaq: SDGR), where he has served in various roles since 1987, including President from January 2008 to December 2016, Senior Vice President from January 2005 to December 2007, and Vice President, Scientific Development and Product Management from January 2003 to December 2004. Prior to joining Schrodinger, Dr. Farid was an Assistant Professor in the Chemistry Department at Rutgers University from July 1994 to December 2001. Dr. Farid currently serves as a member of the board of directors of Schrdinger and Ajax Therapeutics, Inc. a private biotechnology company applying computational chemistry and struture-based technologies to develop small molecules for hematologic malignancies. Dr. Farid was previously a National Institute of Health Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. Dr. Farid received his B.S. in Chemistry from the University of Rochester and his Ph.D. in Chemistry from the California Institute of Technology.- Ramy Farid，自2019年4月起担任Structure Therapeutics公司董事会成员。Farid博士自2017年1月起在薛定谔公司（Nasdaq：SDGR）担任总裁兼首席执行官，自1987年起担任多个职务，包括2008年1月至2016年12月担任总裁、2005年1月至2007年12月担任高级副总裁、2003年1月至2004年12月担任科学发展和产品管理副总裁。在加入薛定谔之前，Farid博士于1994年7月至2001年12月担任罗格斯大学化学系助理教授。Farid博士目前担任Schr dinger和Ajax Therapeutics，Inc.的董事会成员。Ajax Therapeutics，Inc.是一家私营生物技术公司，应用计算化学和基于结构的技术开发用于血液系统恶性肿瘤的小分子。Farid博士以前是宾夕法尼亚大学生物化学和生物物理系的国家卫生研究所博士后研究员。Farid博士在罗切斯特大学获得化学学士学位，在加州理工学院获得化学博士学位。
- Ramy Farid,has served as a member of Structure Therapeutics Inc. board of directors since April 2019. Since January 2017, Dr. Farid has served as the President and Chief Executive Officer at Schrodinger, Inc. (Nasdaq: SDGR), where he has served in various roles since 1987, including President from January 2008 to December 2016, Senior Vice President from January 2005 to December 2007, and Vice President, Scientific Development and Product Management from January 2003 to December 2004. Prior to joining Schrodinger, Dr. Farid was an Assistant Professor in the Chemistry Department at Rutgers University from July 1994 to December 2001. Dr. Farid currently serves as a member of the board of directors of Schrdinger and Ajax Therapeutics, Inc. a private biotechnology company applying computational chemistry and struture-based technologies to develop small molecules for hematologic malignancies. Dr. Farid was previously a National Institute of Health Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. Dr. Farid received his B.S. in Chemistry from the University of Rochester and his Ph.D. in Chemistry from the California Institute of Technology.